First-line usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS)

Sevindik, Ömür Gökmen; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Serin, İstemi

First-line usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS)

dc.authorid	0000-0001-9636-4113
dc.authorid	0000-0003-1508-2822
dc.authorid	0000-0001-6826-7818
dc.contributor.author	Sevindik, Ömür Gökmen
dc.contributor.author	Mutlu, Yaşa Gül
dc.contributor.author	Balık Aydın, Berrin
dc.contributor.author	Serin, İstemi
dc.date.accessioned	2022-07-06T05:38:56Z
dc.date.available	2022-07-06T05:38:56Z
dc.date.issued	2022
dc.department	İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstract	Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS) is a rare paraneoplastic syndrome of an underlying plasma cell disorder (PCD).1 Castleman disease (CD), itself, can also cause symptoms or signs of polyneuropathy, volume overload, cytokine release, but only those with peripheral neuropathy and a plasma cell clone can be classified as classical POEMS.
dc.identifier.citation	Sevindik, Ö. G., Mutlu, Y. G., Balık Aydın, B. ve Serin, İ. (2022). First-line usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS). HemaSphere, 6(7). http://doi.org/10.1097/HS9.0000000000000728
dc.identifier.doi	10.1097/HS9.0000000000000728
dc.identifier.issn	2572-9241
dc.identifier.issue	7
dc.identifier.pmid	35747589
dc.identifier.uri	http://doi.org/10.1097/HS9.0000000000000728
dc.identifier.uri	https://hdl.handle.net/20.500.12511/9562
dc.identifier.volume	6
dc.identifier.wos	000812385100001	en_US
dc.identifier.wosquality	Q1
dc.indekslendigikaynak	Web of Science
dc.indekslendigikaynak	PubMed
dc.institutionauthor	Sevindik, Ömür Gökmen
dc.institutionauthor	Mutlu, Yaşa Gül
dc.institutionauthor	Balık Aydın, Berrin
dc.language.iso	en
dc.publisher	Lippincot Williams & Wilkins
dc.relation.ispartof	HemaSphere	en_US
dc.relation.publicationcategory	Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rights	Attribution 4.0 International	*
dc.rights	info:eu-repo/semantics/openAccess
dc.rights.uri	https://creativecommons.org/licenses/by/4.0/	*
dc.subject	Skin Changes Syndrome (CD-POEMS)
dc.subject	Endocrinopathy
dc.subject	Organomegaly
dc.subject	Monoclonal Gammopathy
dc.subject	Case of Castleman Disease
dc.title	First-line usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS)
dc.type	Article